Online Inquiry
Deferasirox
Cat. No. IC23045
CAS. No. 201530-41-8
Key Features and Details
Category
Inhibitor&Activator
Purity
99.94%
Formula
C21H15N3O4
Product Details
Product Name
Deferasirox
CAS No.
201530-41-8
Molecular Weight
373.36
Synonyms
ICL 670
Formula
C21H15N3O4
Appearance
Solid
Purity
99.94%
SMILES
O=C(O)C1=CC=C(N2N=C(C3=CC=CC=C3O)N=C2C4=CC=CC=C4O)C=C1
Product Overview
Description
Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload.
In Vitro Activity
In LX-2 cells treated with 50 μM deferasirox for 12 h, α1(I)procollagen expression is decreased by 25%, with maximal reductions (10-fold) seen following 24-120 h of treatment. Similarly, α-smooth muscle actin (αSMA) expression is significantly lower. Deferasirox had anti-proliferative effects on HL-60 or KG-1 myeloid leukemia cell lines at a concentration as low as 5 μM . The cytotoxicity is both dose and time dependent. The viability of both EL4 cells and L1210 cells incubated with deferasirox decrease in a concentration-dependent manner.
In Vivo Activity
The tumor is significantly smaller in the SIO mice treated with deferasirox compared with control. Mice treated with DFX showed longer survival than the other groups. Deferasirox has a survival benefit for SIO leukemia murine model in terms of iron chelation and antileukemic therapy.
Storage & Handling
Storage
Powder, -20 °C, 3 years; 4 °C, 2 years
In solvent: -80 °C, 6 months, -20 °C, 1 month.
Shipping
Room temperature in continental US; may vary elsewhere.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Related Products